OpenAlex
PricingAboutJobs
Log inGet started
Work

Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody–Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect

HTML

Year: 2014
Type: article
Source: Molecular Cancer Therapeutics
DOI: 10.1158/1535-7163.mct-13-0926
Authors: Sven Golfier, Charlotte Kopitz, Antje Kahnert, Iring Heisler, Christoph A. Schatz, Beatrix Stelte-Ludwig, Anke Mayer-Bartschmid, Kerstin Unterschemmann, Sandra Bruder, Lars Linden, Axel Harrenga, Peter Hauff, Frank-Detlef Scholle, Beate Müller-Tiemann, Bertolt Kreft, Karl Ziegelbauer
Institution: Bayer (Germany)
Language: English

Topic: Monoclonal and Polyclonal Antibodies Research
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Keywords: antibody-drug conjugates, mesothelin, DM4, maytansinoids, disulfide linker, bystander effect, tumor heterogeneity, tumor targeting, mesothelioma, ovarian cancer, pancreatic cancer, lung adenocarcinoma, patient-derived xenografts, tumor growth inhibition
SDG: Good health and well-being

Open Access status: closed

Funder: Bayer HealthCare
OpenAlex ID: W2138654358
FWCI: 8.232
Cites: 45
Cited by: 266
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms